Showing 1 - 10 of 62
This paper estimates the extent to which market power is a source of production misallocation. Productive inefficiency occurs through more production being allocated to higher cost units of production, and less production to lower-cost production units, conditional on a fixed aggregate quantity....
Persistent link: https://www.econbiz.de/10012116720
This survey examines recent developments in economic research relating to antitrust, paying specific attention to research in the areas of collusion and merger enforcement. Research relating to both collusion and mergers has made significant advances in the last twenty years. With respect to...
Persistent link: https://www.econbiz.de/10012616623
Persistent link: https://www.econbiz.de/10013549223
We study the impact of regulatory regimes on generic competition and pharmaceutical pricing using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. We exploit a detailed panel dataset at product level...
Persistent link: https://www.econbiz.de/10005827125
We analyse how equilibrium locations in location-price games à la Hotelling are affected when firms acquire inputs through bilateral monopoly relations with suppliers. Assuming a duopoly downstream market, we consider the case of two independent input suppliers bargaining with both downstream...
Persistent link: https://www.econbiz.de/10008914348
We study effects of direct-to-consumer advertising (DTCA) in a market with two pharmaceutical firms providing horizontally differentiated (branded) drugs. Patients varying in their susceptability to medication are a priori uninformed of available medication. Physicians making the prescription...
Persistent link: https://www.econbiz.de/10008914353
We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called “index pricing” for a sub-sample of off-patent pharmaceuticals, replacing the...
Persistent link: https://www.econbiz.de/10008918545
We analyse how a patent-holding (incumbent) firm may strategically use advertising ex ante to a¤ect the R&D investments in new (di¤eren- tiated) products, and thus the ex post market structure in the industry. We derive exact conditions for advertising and R&D being substitute strategies for...
Persistent link: https://www.econbiz.de/10008918562
In a model of spatial competition, we analyse the equilibrium outcomes in markets where the product price is exogenous. Using an extended version of the Hotelling model, we assume that firms choose their locations and the quality of the product they supply. We derive the optimal price set by a...
Persistent link: https://www.econbiz.de/10009003086
In many markets, such as education, health care and public utilities, firms are often profit-constrained either due to regulation or because they have non-profit status. At the same time such firms might have altruistic concerns towards consumers. In this paper we study semi-altruistic firms’...
Persistent link: https://www.econbiz.de/10009019285